- Also known as
- Tesamorelin acetate · Egrifta · stabilised GHRH(1-44)
- Class
- Growth hormone-releasing hormone (GHRH) analogue
- Form
- Lyophilised powder in 5 mg and 10 mg vials
- Sizes
- 5 mg · 10 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
- BAC water per size
- 5 mg: 2 mL · 10 mg: 2 mL
What is Tesamorelin?
Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue. Published work on it is in human. The name covers the same material written several ways in the literature, including Tesamorelin acetate, Egrifta and stabilised GHRH(1-44). Its sequence is recorded as 44 amino acids, based on human GHRH(1-44), with a stabilising modification.. 8 of the 8 studies listed below are controlled trials in people. It appears in the literature as Tesamorelin acetate, Egrifta and stabilised GHRH(1-44). It is stocked here as lyophilised powder in 5 mg and 10 mg vials, for laboratory work only. It is not a medicine and is not for use in humans or animals.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Falutz J et al.2010 · J Acquir Immune Defic Syndr · PMID 20101189 | Human, randomised, double-blind, placebo-controlled trial with a safety extension, people with HIV and excess abdominal fat (n=404) | 2 mg s.c. once daily | 6 months, then a 6-month rerandomised extension | Visceral fat fell by 10.9% with tesamorelin vs 0.6% with placebo over 6 months (P < 0.0001), and by about 18% in those continuing for 12 months. IGF-I rose with no change in glucose parameters; the gains were rapidly lost in those switched to placebo. |
| Falutz J et al.2008 · AIDS · PMID 18690162 | Human, randomised, placebo-controlled trial and extension, people with HIV and central fat accumulation (n=410) | 2 mg s.c. once daily | 26 weeks, then a 26-week extension (52 weeks total) | The drop in visceral fat was sustained at 18% over 52 weeks, with triglycerides down 51 mg/dl (both P < 0.001 vs baseline). Adverse events were comparable between phases and glucose changes were not clinically significant; visceral fat reaccumulated after stopping. |
| Stanley TL et al.2014 · JAMA · PMID 25038357 | Human, randomised, double-blind, placebo-controlled trial, people with HIV and abdominal fat accumulation (n=50) | 2 mg s.c. once daily | 6 months | Visceral fat changed by −34 cm² with tesamorelin vs +8 cm² with placebo (P = .005), and liver fat fell by a median 2.0% vs a rise of 0.9% (P = .003). Fasting glucose rose at 2 weeks, but glucose changes over 6 months were not significant. |
| Stanley TL et al.2019 · Lancet HIV · PMID 31611038 | Human, randomised, double-blind, multicentre trial, people with HIV and non-alcoholic fatty liver disease (n=61) | 2 mg once daily | 12 months, then a 6-month open-label phase | Hepatic fat fraction fell by an absolute 4.1% more than with placebo (p = 0.018), a 37% relative reduction. After 12 months 35% on tesamorelin and 4% on placebo had a fat fraction under 5%; fasting glucose and HbA1c did not differ between groups. |
| Clemmons DR et al.2017 · PLoS One · PMID 28617838 | Human, randomised, placebo-controlled trial, patients with type 2 diabetes (n=53) | 1 or 2 mg | 12 weeks | There were no significant differences between groups in relative insulin response, fasting glucose, HbA1c or overall diabetes control. Total and non-HDL cholesterol fell significantly in the 2 mg group. |
| Makimura H et al.2014 · J Clin Endocrinol Metab · PMID 24178787 | Human, randomised, double-blind, placebo-controlled trial, obese adults with reduced GH secretion (n=39) | Not stated in the abstract | 12 months | IGF-I rose by 102.9 μg/L with tesamorelin vs 22.8 μg/L with placebo (P = .02). Increases in IGF-I correlated with faster phosphocreatine recovery after exercise, a marker the authors link to mitochondrial function. |
| Adrian S et al.2019 · J Frailty Aging · PMID 31237318 | Human, secondary analysis of two randomised trials, people with HIV and abdominal obesity (193 tesamorelin responders, 148 placebo) | Not stated in the abstract | 26 weeks | Among responders, tesamorelin was associated with significantly greater increases in the density of four trunk muscle groups and in lean muscle area (all p < 0.005) compared with placebo. |
| Ellis RJ et al.2025 · J Infect Dis · PMID 39813152 | Human, randomised, open-label phase 2 trial vs standard of care, people with HIV, abdominal obesity and neurocognitive impairment (n=73) | 2 mg s.c. daily | 6 months | Waist circumference fell more with tesamorelin (median difference −2.7 cm; P = .015), but the change in neurocognitive performance did not differ between groups (P = .673). |
What these studies don't show: Trials exist; their scope is narrower than it first appears. Trial populations are selected, endpoints are often surrogate measures rather than outcomes, and follow-up rarely runs long. None of it establishes safety outside the conditions each trial ran under. Purity data confirms what is in the vial and says nothing about whether a compound works.
Every study links to its PubMed record. See all Tesamorelin studies in the research library →
Tesamorelin price in Canada: 5mg and 10mg vials
Buy Tesamorelin in Canada in 2 vial sizes and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 5 mg | $61.50 | $12.30/mg |
| 10 mg | $85.50 | $8.55/mg |
Starter kit
Is Tesamorelin available in Canada?
Tesamorelin is an authorized prescription medicine in Canada. Health Canada publishes that database openly, so the status can be checked rather than taken on trust. Authorized in Canada as EGRIFTA (Theratechnologies), DIN 02438712. That authorization covers the licensed product, not research material, and Borealis Peptides supplies this for laboratory work only. How Health Canada treats research peptides →
Side effects reported in studies
Each statement is tied to the study that reported it. Tolerability observations from the cited papers appear below in the authors own terms. Human work of this size does not establish a safety profile.
Tesamorelin FAQ
What is Tesamorelin?
The literature describes Tesamorelin as growth hormone-releasing hormone (GHRH) analogue. The published work on it is in human. Borealis Peptides supplies it as lyophilised powder in 5 mg and 10 mg vials for in-vitro laboratory research. It is not authorized as a medicine and is not for use in any living subject. Each study on this page carries its model and the outcome its authors recorded.
Where can I buy Tesamorelin in Canada?
Direct from Borealis Peptides, held in Canadian stock so nothing crosses a border on its way to you. Stocked in 5 mg and 10 mg vials. Purity is confirmed by HPLC batch by batch, and we supply for laboratory research only.
Is Tesamorelin legal in Canada?
Tesamorelin is an authorized prescription medicine in Canada. Authorized in Canada as EGRIFTA (Theratechnologies), DIN 02438712. That authorization covers the licensed product, not research material, and Borealis Peptides supplies this for laboratory work only. Health Canada has said that "Research Use Only" labelling does not make a product legal to use in a person, so we treat it as a description of what the material is supplied for rather than a permission. Lawful use in your own setting is yours to establish.
How much Tesamorelin should I use?
Borealis Peptides gives no dosing, protocols or reconstitution volumes, and will not provide them on request. In laboratory work the amount follows from the study design, which a supplier cannot sensibly set. The figures on this page are what specific published studies used in their own models: a record of what was done, not a recommendation.
What human evidence is there for Tesamorelin?
Of the 8 studies cited, 8 are controlled trials in people and the rest are animal or cell work. Each row names its model, the amount used and what the authors reported, so the weight of each study can be judged directly rather than through a summary.
How long does Tesamorelin keep?
Hold sealed vials at −20 °C, dry and dark. In solution it is kept at 2–8 °C. The lyophilised powder tolerates ambient temperature in transit, so it ships without ice and goes into the fridge on arrival. Repeated freeze-thaw cycles and light exposure are the real risks, not the shipping.
How is the purity of Tesamorelin confirmed?
Every batch is tested by HPLC before it is sold, and the certificate refers to the batch in your vial rather than to the product in general. Keeping that batch number with your records is what makes an observation reproducible later. Certificates are available on request.
How does Tesamorelin compare with Ipamorelin and CJC-1295 (no DAC)?
They are different compounds with different published records, and this site does not rank them. Ipamorelin and CJC-1295 (no DAC) have 8 cited studies and 6 cited studies on their page against 8 here. Set the two evidence tables side by side and the difference is visible directly.
Compare with
Related compounds
Ipamorelin
Growth hormone secretagogue (ghrelin receptor agonist)
Add 2 more to save 4%
CJC-1295 (no DAC)
Growth hormone-releasing hormone (GHRH) analogue
Add 2 more to save 4%
